ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Private company trial initiations stand out in the latest week’s disclosures.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
Despite magrolimab’s latest flop, efforts to target CD47 continue.
The latest clinical study listings reveal KRAS-targeting projects, ADCs and others starting phase 1.